Haige Shen

957 total citations
11 papers, 304 citations indexed

About

Haige Shen is a scholar working on Molecular Biology, Oncology and Civil and Structural Engineering. According to data from OpenAlex, Haige Shen has authored 11 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 1 paper in Civil and Structural Engineering. Recurrent topics in Haige Shen's work include Colorectal Cancer Treatments and Studies (2 papers), TGF-β signaling in diseases (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Haige Shen is often cited by papers focused on Colorectal Cancer Treatments and Studies (2 papers), TGF-β signaling in diseases (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Haige Shen collaborates with scholars based in China, United States and Australia. Haige Shen's co-authors include Aaron Osborne, Gabriele E. Lang, Ursula Schmidt‐Erfurth, Reinier O. Schlingemann, Paolo Lanzetta, Ortrud Gerstner, Pascale Massin, Paul Mitchell, Frank G. Holz and Yu Wang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Ophthalmology.

In The Last Decade

Haige Shen

10 papers receiving 294 citations

Peers

Haige Shen

OPHTH

RNMI

ONCOL

PRM

Monica Sevilla United States

Mingzhen Yuan China

Gabriella Widmer Switzerland

Jianling Yang China

Sara Brandi Bloch Denmark

Edward Dervan Ireland

Emi Ueda Japan

Laura Wilson United States

Rana’a T. Al‐Jamal Finland

James Warburton Switzerland

Monica Sevilla United States

Haige Shen

199 ×0.8

OPHTH

211 ×1.0

RNMI

45 ×0.7

12 ×0.5

ONCOL

21 ×1.5

PRM

Citations per year, relative to Haige Shen Haige Shen (= 1×) peers Monica Sevilla

Countries citing papers authored by Haige Shen

Since Specialization

Citations

This map shows the geographic impact of Haige Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haige Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haige Shen more than expected).

Fields of papers citing papers by Haige Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haige Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haige Shen. The network helps show where Haige Shen may publish in the future.

Co-authorship network of co-authors of Haige Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Haige Shen. A scholar is included among the top collaborators of Haige Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haige Shen. Haige Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ai, Xinghao, Lin Wu, Zhi-Hua Li, et al.. (2025). A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3013–3013. 3 indexed citations

Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511. 14 indexed citations

Guo, Ye, Zishu Wang, Huan Zhou, et al.. (2024). First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors. BMC Cancer. 24(1). 444–444. 7 indexed citations

Lickliter, Jason D., Shuang Wang, Wenxin Zhang, et al.. (2023). A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects. Clinical and Translational Science. 16(9). 1691–1703. 15 indexed citations

Guo, Ye, Zishu Wang, Huan Zhou, et al.. (2023). GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study.. Journal of Clinical Oncology. 41(16_suppl). e15117–e15117. 2 indexed citations

Shen, Haige, et al.. (2023). Experimental study on the effect of cutting parameters to dust production patterns of different brittle coal. International Journal of Coal Preparation and Utilization. 44(2). 154–169. 1 indexed citations

Mai, Hai‐Qiang, Ye Guo, Kunyu Yang, et al.. (2023). A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).. Journal of Clinical Oncology. 41(16_suppl). 6026–6026. 4 indexed citations

Zhou, Keshu, Wenbin Qian, Aimin Zang, et al.. (2022). First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies. Blood. 140(Supplement 1). 9473–9474. 7 indexed citations

Lucas, Joseph E., et al.. (2018). Trans-study projection of genomic biomarkers in analysis of oncogene deregulation and breast cancer. Oxford University Press eBooks.

10.

Schmidt‐Erfurth, Ursula, Gabriele E. Lang, Frank G. Holz, et al.. (2014). Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema. Ophthalmology. 121(5). 1045–1053. 245 indexed citations

11.

Ji, Chunlin, Haige Shen, & Michael L. West. (2010). Bounded Approximations for Marginal Likelihoods. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact